We are pleased to announce that Nordic Bioscience's liver team will be attending EASL 2023 (European Association for the Study of the Liver) conference in Vienna. This significant international event brings together leading experts and researchers in liver disease to discuss the latest advancements in research and patient care.
Our liver team will present groundbreaking findings on chronic liver diseases, with a particular focus on the prognostic and predictive value of PRO-C3. This innovative biomarker has demonstrated its ability to accurately assess liver fibrosis progression in patients, providing valuable insights for both clinicians and drug developers. By sharing this research, Nordic Bioscience aims to contribute to the understanding and management of liver fibrosis, fostering collaboration and driving progress in liver disease research.
